12th March 2021
Mucormycosis emerging as a ‘new worry’ among Covid patients
Pharmabiz India, 12 March 2021:
BSV is indigenously developing and manufacturing the formulation of Amphotericin B including Liposomal Amphotericin B and Lipid Complex Amphotericin B – the anti-fungal medications that have been recommended for use in life-threatening fungal infections such as mucormycosis. BSV is the first company in India to get the Drugs Controller General of India (DCGI) approval for Liposomal Amphotericin B, the anti-fungal medication used in the treatment of this condition and is also marketing Liposomal Amphotericin B in India and exporting it to many other countries.
BSV has been a pioneer in the development of blood components and therapeutic antibody products for infectious and non-infectious diseases. For over four decades, BSVL has focused on utilizing its scientific resources to develop several biological, biotechnology and pharmaceutical products to treat various types of diseases, contributing to preserve, protect and enhance the quality of life. We aim to be a leading biopharmaceutical company driven by people & science to set benchmarks in patient outcomes in Women’s Health, Critical Care & Emergency Medicine.
For more information, please contact:
Irawati Gowariker, BSV, Irawati.email@example.com